News

Mr Kay will join Algeta from Renovo, where he was executive director of commercial operations. He brings more than 25 years of commercial experience in the pharmaceutical sector.

In connection with the completion of the acquisition, Affymetrix is paying approximately $73 million in cash to acquire Panomics.Founded in 2000, Panomics offers a platform of reagents and

According to the company, Eurartesim, a Phase III product candidate, aims to treat uncomplicated Plasmodium falciparum malaria in adults and children, while reducing the potential for re-infection. The

The marketing authorization is supported by data from two international, double-blind, randomized, placebo-controlled Phase III clinical trials in patients with hyperphenylalaninemia (HPA) due to phenylketonuria (PKU). According to

According to the company, both the lumican monoclonal antibody and the keratocan monoclonal antibody are IgM antibodies that are affinity purified on a thiophilic column. The lumican antibody

HemaQuest performed two different trials. In the first placebo-controlled clinical study, 32 healthy volunteers were given single doses of HQK-1001, ranging from two to 20mg/kg. This trial was

The Phase I trial is an open label study being conducted at Erasmus University Medical Center, Rotterdam, The Netherlands under the direction of M de Jonge. The objectives

In the study, patients with relapsed or refractory multiple myeloma who received romidepsin in combination with Velcade and dexamethasone had an overall response rate of 85% (17/20). Approximately

This first study was a double-blind, placebo-controlled, randomized, single, oral, ascending dose trial performed in 71 healthy male and female volunteers. The primary objective of the Phase I